NikoleV Posted May 5, 2022 Share Posted May 5, 2022 Progress in Targeting MET Drivers in Advanced NSCLC Posted on March 4, 2022 Juhi Kunde, MA, LUNGevity Science WriterDr. Edward Garon MET is a gene that encodes for a MET protein. It is an important signaling protein known to play many different important roles, from the development of embryos to wound healing in adults. However, when specific MET gene alterations occur, they can also lead to the development of non-small cell lung cancer (NSCLC). Among patients with NSCLC, approximately 3%-4% have these specific MET alterations. Researchers have developed treatments that target these altered MET pathways and shrink tumors. Two of these targeted therapies have been approved by the US Food and Drug Administration (FDA). LUNGevity Foundation spoke with Edward Garon, MD, director of thoracic oncology at the UCLA Jonsson Comprehensive Cancer Center and member of LUNGevity’s Scientific Advisory Board, to learn more about MET targeted therapies and the exciting future of MET-based treatments. Read more of the blog here: https://www.lungevity.org/blogs/progress-in-targeting-met-drivers-in-advanced-nsclc Tom Galli and jack14 2 Quote Link to comment Share on other sites More sharing options...
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.